Welcome to Aclipse Therapeutics

Aclipse Therapeutics develops novel and highly differentiated therapeutics to treat life-threatening and severe diseases. Our approach leverages genomic, proteomic and biomarker data to develop disease-modifying drug candidates and potential biomarkers.

Aclipse Therapeutics focuses on molecular pathways that regulate inflammation, cellular stress, protein misfolding. We focus on neuromuscular diseases that are strongly impacted by these molecular pathways. We believe that developing patient stratification approaches will allow for the identification of potential drug responders and thereby improve patient outcomes.

With M107 on track to enter a Phase 2 clinical trial in gastroparesis and M102 to enter a Phase 1 clinical trial in ALS next year, Aclipse continues its transition to a clinical stage development company dedicated to delivering breakthrough medicines for patients.

Therapeutics

M107 is the first potential disease-modifying drug candidate for the treatment of gastroparesis, a chronic and serious gastrointestinal disease affecting stomach nerves and muscles resulting in stomach paralysis and delayed stomach emptying. M107 seeks to treat the underlying pathology of gastroparesis by switching human pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages. M107 lowers inflammation in the stomach and increases the population of the interstitial cells of Cajal (i.e., the pacemaker cells of the stomach), allowing for increased stomach emptying and function and decreased fibrosis of the stomach pylorus.

M102 is a potential disease-modifying drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig’s disease. ALS is a fatal, progressive neurodegenerative disease affecting voluntary muscles. ALS is also a complex disease with multiple disease pathomechanisms. M102 takes a broad mechanistic approach to treat ALS with dual activation of NRF2 and HSF1 pathways affecting multiple ALS pathomechanisms including oxidative stress, neuro-inflammation, mitochondrial dysfunction, and protein misfolding. We are also developing patient stratification approaches for sporadic ALS patients that may allow for improved clinical outcomes.

Team

Aclipse management team has extensive experience in pharmaceutical research, regulatory and clinical development, manufacturing, and drug approvals. Our team has a strong proven track record in business development, including IPOs, M&As, in- and out-licensing, acquisitions, and collaborations totaling over $13 billion in transactions. Aclipse management team previously exited Thar Pharmaceuticals (acquired by Grünenthal GmbH), Lev Pharmaceuticals (acquired by ViroPharma, now Takeda), and ASK Bio (acquired by Bayer).

We're here to answer any questions.
Looking to connect with us?